Seagen

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997, and is headquartered in Bothell, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Seagen reports robust Q4 earnings, poised for growth and innovation

Seagen's strong financial performance, focus on key products like ADCETRIS and PADCEV, and strategic investments in R&D position the company for continued growth.
While facing challenges in managing expenses and navigating competitive markets, Seagen's commitment to innovation and pipeline development presents opportunities for future success.
Overall, Seagen's performance in Q4 2022 reflects a company poised for growth, with a clear strategic focus on optimizing its commercial portfolio and advancing clinical programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.  The company was founded in 1997 and is headquartered in Bothell, Washington.

Seagen reported second quarter revenue of $498 million, up 28%, beating analyst expectations.

Seagen reports $498M in Q2 revenue, stays silent on reported sale to Merck

Seagen reported a narrower-than-expected second-quarter loss and strong sales. But SGEN stock was unmoved in late action.

Seagen Crushes Quarterly Forecasts With Narrower-Than-Expected Losses

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) reported financial results today for the second quarter ended June 30, 2022. The Company also highlighted PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), ADCETRIS® (brentuximab vedotin) and TIVDAK® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its deep and diverse oncology pipeline. “Seagen once again delivered strong commercial performance with record quarterly net product sales

Seagen Reports Second Quarter 2022 Financial Results

Merck

Seattle area biotech company Seagen released early data on a trial of its drug Padcev combined with Merck's Keytruda in patients with certain types of urothelial cancer.

Seagen releases data on combination therapy with Merck drug amid acquisition reports

Nearly two-thirds of bladder cancer patients responded to a combination from Seagen and Merck, leading SGEN stock to jump Tuesday. The post Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?

Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?

Shares of Seagen Inc. SGEN, +0.71% gained 2.5% in premarket trading on Tuesday after the company said an early-stage clinical trial evaluating its investigational treatment for urothelial cancer in combination with Merck & Co. Inc.'s MRK, +0.47% Keytruda met its primary endpoint. Seagen is developing the therapy, enfortumab vedotin, with Astellas Pharma Inc. jp:TSE:4503 ; it received a Breakthrough Therapy designation in early 2020.

Seagen shares positive data for bladder cancer drug; stock is up 2.5%

– Companies plan to discuss results with regulatory authorities – TOKYO and BOTHELL, Wash. , July 26, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D.

Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer

BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K evaluating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer (l

Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer

Daiichi Sankyo Co Ltd

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) confirmed today that the U.S. District Court for the Eastern District of Texas has entered judgment on the April 8, 2022 jury verdict finding that ENHERTU® infringes Seagen's U.S. Patent 10,808,039 (the '039 patent), that the infringement was willful, and awarding Seagen $41.8 million in damages. Despite the jury's finding of willfulness, the Court decided under the totality of the c

Daiichi Sankyo Confirms that a Texas Court has Entered Judgment on the Jury Verdict in Seagen Patent Dispute

Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?

Is Merck Stock A Buy With A Possible Seagen Buyout Right Around The Corner?

Merck & Co.'s roughly $40 billion deal for Seagen Inc. is unlikely to be finalized ahead of the pharmaceutical giant's earnings later this month, though the talks remain on track, according to people familiar with the matter.

Merck deal for Seagen unlikely to be finalized ahead of earnings later this month, sources say

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Seattle Genetics (SGEN) Now Trades Above Golden Cross: Time to Buy?

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its second quarter 2022 financial results on Thursday, July 28, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Conference call and webcast information: Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 101

Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2022 Financial Results on July 28, 2022

A new Wall Street Journal report revealed that Merck is in “advanced talks” to acquire Seattle-area biotech giant Seagen in a deal that could be worth $40 billion or more.

Report: Merck in ‘advanced talks' to acquire Seattle-area biotech giant Seagen for around $40B

Reportedly, Merck (MRK) could offer at least $40 billion to buy Seagen (SGEN). If both companies go through with the deal, it will expand Merck's oncology portfolio/pipeline.

Merck (MRK) in Advanced Talks to Buy Seagen (SGEN) Per WSJ

Shares of Seagen Inc (NASDAQ: SGEN) are up 3.0% this morning on a report that Merck & Co Inc (NYSE: MRK) is in advanced talks to buy the cancer drug specialist for at least $40 billion. Dr Gottlieb reacts to the news According to the Wall Street Journal, the pharma giant is willing to pay […] The post Merck nears Seagen takeover: ‘question is how does FTC look at this?

Merck nears Seagen takeover: ‘question is how does FTC look at this?'

Seagen (SGEN) stock is getting a boost on Thursday as rumors circulate that Merck (MRK) is considering a buyout of the biotechnology company. The post Seagen (SGEN) Stock Pops on Merck Buyout Rumors appeared first on InvestorPlace.

Seagen (SGEN) Stock Pops on Merck Buyout Rumors

Seagen Inc (NASDAQ: SGEN) shares are trading higher Thursday following reports suggesting Merck & Company Inc (NYSE: MRK) is in advanced talks to acquire the company. According to a Wall Street Journal report citing people familiar with the matter, the two companies are.

Why Merck Is Sending Seagen Stock Higher Today

Merck & Co Inc (NYSE: MRK) is in advanced talks to acquire Seagen Inc (NASDAQ: SGEN), and an agreement on a purchase is expected in the next few weeks, Wall Street Journal reported citing people familiar with the matter. The potential deal could be worth roughly $40.

Merck's Potential Buyout Of Seagen Expected Within Next Few Weeks: Report

The two companies are discussing a price for Seagen above $200-a-share, The Wall Street Journal reported.

Merck Is Now in Advanced Talks to Buy Cancer Biotech Seagen for $40 Billion: Report

Merck & Co is reportedly in talks to acquire biotech company Seagen Inc. in a nearly $40 billon deal that would add to the company's cancer drug portfolio.

Merck in talks to buy cancer biotech Seagen: report

Drugmaker Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen Inc in a deal that could be worth roughly $40 billion or more, the Wall Street Journal reported on Wednesday.

Merck in advanced talks to buy Seagen in $40-billion deal - WSJ

Fate Therapeutics

IVERIC bio Inc

Karuna Therapeutics Inc

Madrigal Pharmaceuticals

Nkarta, Inc.

Takeda Pharmaceutical

One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration approval. If that happens, Jefferies analyst Chris Howerton believes the treatment should have “no issue” topping annual sales of $1 billion, reported BioPharma Dive.

Trial Results Set to Make or Break Small-Cap Pharma Stocks

American Electric Power Company

Aspen Technology Inc

Dollar Tree

T-Mobile US

We have narrowed our search to five Nasdaq Composite listed stocks that have witnessed a double-digit rally year to date. These are: AEP, AZPN, SGEN, DLTR and TMUS.

Top 5 Nasdaq Stocks Flying High Amid Index's Bloodbath in 1H

Bayer AG

Loncar Cancer Immunotherapy ETF

Oncology remains the fastest growing pharma segment, where innovation is largely driven by emerging small companies. The global oncology market is estimated at c US$175–180bn and is anticipated to more than double from current levels within the next seven years to address the rising incidence rates.

News for Seagen Stock (SGEN)